Characteristics and disease response in patients with relapsed disease prior to TAA-T infusion.
| Patient ID . | Age/ sex . | Diagnosis indication for BMT . | Donor and transplant type . | Time to evidence of disease after transplant (days) . | Status at relapse . | Postrelapse treatment . | Status at TAA-T cell infusion (evaluation timepoint preinfusion) . | Day post-BMT at time of TAA-T infusion . | ALC at first TAA-T cell infusion (k/IU) . | TAA-T dose level (number of doses) . | Best response postinfusion . | Time to relapse postinfusion (days) . | Survival postinfusion (days) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 24 Years/M | B-ALL Ph+ | HLA = sibling TBI MA | 75 | CNS3 BM 15% blasts | Azacitidine,DLI, XRT, TKI, IT chemotherapy | BCR/ABL+, CNS− (34 d) | +896 | 0.27 | 1 (1) | SD | 21 | 28 |
| 2 | 64 Years/M | MDS/AML | HLA = sibling NMA | 155 | BM 27% blasts | HIDAC × 2 | CR (9 d) | +330 | 0.77 | 1 (1) | PD | 42 | 169 |
| 3 | 48 Years/F | B-ALL | HLA = sibling MA | 56 | Extramedullary leukemia | VP16/MT × 1, blinatumomab, Cytarabine | PD (3 d) | +423 | 2.21 | 2 (1) | SD | 19 | 255 |
| 4 | 54 Years/M | MDS/AML tri8,13,20 MLL RUNX1T1 | HLA = sibling NMA | 107 | BM 80% blasts | HIDAC × 2 | CR (17 d) | +184 | 0.37 | 2 (1) | PD | 36 | 137 |
| 5 | 68 Years/F | MDS/AML tri8, 5q-, mo7 | Haplo son NMA | 117 | BM 5% blasts | Azacitidine × 3 | CR (9 d) | +222 | 1.43 | 3 (3) | CCR | 167 | 422 |
| 6 | 70 Years/M | MDS/AML tri8, 14 | Haplo son NMA | 179 | BM 80% blasts | ACDVP16 × 1 | CR (53 d) | +283 | 0.86 | 3 (1) | PD | 53 | 95 |
| 7 | 58 Years/M | AML 9q- tri21, Mut CEBPa,Kit, IK2F | HLA = sibling NMA | 289 | BM 60% blasts | ACDVP16 × 1HIDAC ×2 | CR (123 d) | +455 | 1.81 | 3 (4) | CCR | 518 | 1150 |
| 8 | 9 Years/F | B-ALL Ph+ TP53 mutation | HLA = sibling MA | N/A | Persistent positive BCR/ABL | TKI | Persistent positive BCR/ABL, MRD− (15 d) | +231 | 2.82 | 4 (2) | CCR (MRD−, BCR/ABL undetectable) | N/A (MRD+ day 105) | 1160+ |
| 9 | 21 Years/M | AML GATA2 FLT3+ | Haplo mother NMA | No relapse after 2nd transplant (relapsed 310 d after 1st transplant) | Marrow morphology “suspicious” for AML | Second BMT, azacitidine | CR (28 d) | +167 | 1.09 | 4 (1) | CCR | N/A | 812+ |
| 10 | 4 Years/F | AML MLL rearrangement | Haplo father RI | 271 post–2nd transplant (relapsed 180 d after 1st transplant) | BM blasts 0.08% (0.48% 3 mo later) | IFNa, DLI | MRD 0.01% (6 d) | +460 | 2.12 | 4 (1) | PR | 90 | 323 |
| 11 | 61 Years/M | MDS/AML EBB1, p53 mutation | MiniHaplo son NMA | 115 | BM blasts 20% | Azacitidine (post–TAA-T cells) | Persistent blasts (20 d) | +135 | 0.71 | 4 (1) | SD | 64 (PD) | 150 |
| Patient ID . | Age/ sex . | Diagnosis indication for BMT . | Donor and transplant type . | Time to evidence of disease after transplant (days) . | Status at relapse . | Postrelapse treatment . | Status at TAA-T cell infusion (evaluation timepoint preinfusion) . | Day post-BMT at time of TAA-T infusion . | ALC at first TAA-T cell infusion (k/IU) . | TAA-T dose level (number of doses) . | Best response postinfusion . | Time to relapse postinfusion (days) . | Survival postinfusion (days) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 24 Years/M | B-ALL Ph+ | HLA = sibling TBI MA | 75 | CNS3 BM 15% blasts | Azacitidine,DLI, XRT, TKI, IT chemotherapy | BCR/ABL+, CNS− (34 d) | +896 | 0.27 | 1 (1) | SD | 21 | 28 |
| 2 | 64 Years/M | MDS/AML | HLA = sibling NMA | 155 | BM 27% blasts | HIDAC × 2 | CR (9 d) | +330 | 0.77 | 1 (1) | PD | 42 | 169 |
| 3 | 48 Years/F | B-ALL | HLA = sibling MA | 56 | Extramedullary leukemia | VP16/MT × 1, blinatumomab, Cytarabine | PD (3 d) | +423 | 2.21 | 2 (1) | SD | 19 | 255 |
| 4 | 54 Years/M | MDS/AML tri8,13,20 MLL RUNX1T1 | HLA = sibling NMA | 107 | BM 80% blasts | HIDAC × 2 | CR (17 d) | +184 | 0.37 | 2 (1) | PD | 36 | 137 |
| 5 | 68 Years/F | MDS/AML tri8, 5q-, mo7 | Haplo son NMA | 117 | BM 5% blasts | Azacitidine × 3 | CR (9 d) | +222 | 1.43 | 3 (3) | CCR | 167 | 422 |
| 6 | 70 Years/M | MDS/AML tri8, 14 | Haplo son NMA | 179 | BM 80% blasts | ACDVP16 × 1 | CR (53 d) | +283 | 0.86 | 3 (1) | PD | 53 | 95 |
| 7 | 58 Years/M | AML 9q- tri21, Mut CEBPa,Kit, IK2F | HLA = sibling NMA | 289 | BM 60% blasts | ACDVP16 × 1HIDAC ×2 | CR (123 d) | +455 | 1.81 | 3 (4) | CCR | 518 | 1150 |
| 8 | 9 Years/F | B-ALL Ph+ TP53 mutation | HLA = sibling MA | N/A | Persistent positive BCR/ABL | TKI | Persistent positive BCR/ABL, MRD− (15 d) | +231 | 2.82 | 4 (2) | CCR (MRD−, BCR/ABL undetectable) | N/A (MRD+ day 105) | 1160+ |
| 9 | 21 Years/M | AML GATA2 FLT3+ | Haplo mother NMA | No relapse after 2nd transplant (relapsed 310 d after 1st transplant) | Marrow morphology “suspicious” for AML | Second BMT, azacitidine | CR (28 d) | +167 | 1.09 | 4 (1) | CCR | N/A | 812+ |
| 10 | 4 Years/F | AML MLL rearrangement | Haplo father RI | 271 post–2nd transplant (relapsed 180 d after 1st transplant) | BM blasts 0.08% (0.48% 3 mo later) | IFNa, DLI | MRD 0.01% (6 d) | +460 | 2.12 | 4 (1) | PR | 90 | 323 |
| 11 | 61 Years/M | MDS/AML EBB1, p53 mutation | MiniHaplo son NMA | 115 | BM blasts 20% | Azacitidine (post–TAA-T cells) | Persistent blasts (20 d) | +135 | 0.71 | 4 (1) | SD | 64 (PD) | 150 |
ACDVP16, cytarabine, daunorubicin, etoposide; B-ALL, B-cell acute lymphoblastic leukemia; BM, bone marrow; CNS, central nervous system; haplo, haploidentical; HIDAC, high-dose cytarabine; HLA = sibling, HLA-matched sibling; IT, intrathecal; MA, myeloablative; MDS, myelodysplastic syndrome; MTX, methotrexate; NMA, nonmyeloablative; Ph+, Philadelphia chromosome–positive; RI, reduced intensity; TBI, (total body irradiation; TKI, tyrosine kinase inhibitor; XRT, radiation therapy.